ILK and breast cancer: The results show that, indeed, disruption of cellular microtubules by MTAs used in the treatment of breast cancer affects the biogenesis and secretion of sEVs as well as specific sEV cargos, including ILK, with differences noted between microtubule stabilizers and microtubule destabilizers.